Ratio Revelations: Humacyte Inc (HUMA)’s Financial Metrics in the Spotlight

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Humacyte Inc (NASDAQ: HUMA) closed the day trading at $5.17 down -1.34% from the previous closing price of $5.24. In other words, the price has decreased by -$1.34 from its previous closing price. On the day, 6.78 million shares were traded. HUMA stock price reached its highest trading level at $5.36 during the session, while it also had its lowest trading level at $5.0.


For a better understanding of HUMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.37 and its Current Ratio is at 8.37. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.61.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 11, 2023, initiated with a Buy rating and assigned the stock a target price of $6.

On August 14, 2023, Piper Sandler Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $2.75 to $3.50.

On June 22, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on June 22, 2023, with a $6 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 12 ’24 when Dougan Brady W sold 271,518 shares for $7.30 per share. The transaction valued at 1,982,081 led to the insider holds 4,559,140 shares of the business.

Niklason Laura E sold 271,518 shares of HUMA for $1,982,081 on Jun 12 ’24. The President, CEO and Director now owns 4,559,140 shares after completing the transaction at $7.30 per share. On Jun 11 ’24, another insider, Niklason Laura E, who serves as the President, CEO and Director of the company, sold 358,630 shares for $7.08 each. As a result, the insider received 2,537,943 and left with 4,830,658 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 615664320 and an Enterprise Value of 518729120.

Stock Price History:

The Beta on a monthly basis for HUMA is 1.51, which has changed by 0.7827586 over the last 52 weeks, in comparison to a change of 0.26238096 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $1.96. The 50-Day Moving Average of the stock is -6.64%, while the 200-Day Moving Average is calculated to be 42.03%.

Shares Statistics:

Over the past 3-months, HUMA traded about 2.20M shares per day on average, while over the past 10 days, HUMA traded about 2582910 shares per day. A total of 103.67M shares are outstanding, with a floating share count of 91.98M. Insiders hold about 22.76% of the company’s shares, while institutions hold 19.51% stake in the company. Shares short for HUMA as of 1715731200 were 4190449 with a Short Ratio of 2.23, compared to 1713139200 on 3941934. Therefore, it implies a Short% of Shares Outstanding of 4190449 and a Short% of Float of 4.64.

Earnings Estimates

The market rating for Humacyte Inc (HUMA) is a result of the insights provided by 5.0 analysts actively involved in the assessment.On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.25, while EPS last year was -$0.22. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.22 and low estimates of -$0.27.

Analysts are recommending an EPS of between -$0.91 and -$1.07 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.83, with 5.0 analysts recommending between -$0.64 and -$0.97.

Revenue Estimates

Based on 5 analysts’ estimates, the company’s revenue will be $30.85M in the next fiscal year. The high estimate is $42.6M and the low estimate is $12.53M.

Most Popular